TORONTO, May 30, 2018 /PRNewswire/ – Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) (“Liberty” or the “Company”) is pleased to announce that it has signed a licensing agreement with Isodiol International Inc. (“Isodiol”), a leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products, to provide a complementary suite of medical cannabis products to patients in Florida and Massachusetts.

Liberty is proud to team up with Isodiol, a company renowned for its ability to process and extract high purity CBD on an industrial scale. We are committed to providing all our patients across Massachusetts and Florida with an extensive selection of medical cannabis and derivative products.

George Scorsis, Director and CEO of Liberty

Isodiol is a fantastic addition to our rapidly expanding portfolio of celebrated brands as we continue to execute on our aggressive growth strategy to roll out dispensary locations and product offerings across Florida and Massachusetts.

The Isodiol branded products will be available for sale through Liberty’s Cannabis Education Centers. The Company continues to add an assortment of products and brands that allow Liberty to address the needs of all patients in a variety of forms. This exciting new product line will complement Liberty’s expanding lineup of brands to be offered to Florida and Massachusetts patients, including Aphria, Solei, Mary’s Medicinals and incredibles. The agreement with Isodiol allows Liberty to license and produce the following products:

Isodiol’s BIOACTIVE CBD Isodiol’s CannaCeuticals Isodiol’s IsoDerm Isodiol’s IsoSport products Isodiol’s Rapid Cream Isodiol’s Rapid Patch Isodiol’s Pot-O-Coffee

Isodiol is excited to partner with a company that is equally committed to bring health and wellness to consumers around the globe. Florida and Massachusetts will further expand the marketplace for Isodiol and we look forward to establishing a long-term partnership with Liberty with further expansion down the road.

Marcos Agramont, CEO of Isodiol

Possessing the unique ability to export its pharmaceuticals grade, natural hemp derived Cannabidiol (CBD) product technology anywhere in the

Read More Here...